临床试验/NCT07304193

NCT07304193Enrolling By Invitation不适用

Clinical and Genetic Aspects of Fetuses With Sex-chromosome Disorders

University of Aarhus1 个研究点分布在 1 个国家目标入组 120 人开始时间: 2024年1月1日最近更新: 2026年1月8日

试验速览

阶段: 不适用
状态: Enrolling By Invitation
发起方: University of Aarhus
入组人数: 120
试验地点: 1
主要终点: DNA methylation profile

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To conduct a comprehensive clinical investigation of electively aborted fetuses with sex chromosome disorders and their placentas, in parallel with analyses of epigenetic alterations and changes in gene expression in these fetuses and their placentas, with the aims to:

delineate how variations in sex chromosome number affect the epigenetic and genetic mechanisms regulating gene expression in the placenta and in multiple fetal tissues in fetuses with sex chromosome disorders;
identify the epigenetic and genetic mechanisms and placental and fetal alterations that underlie the phenotypic manifestations observed in fetuses with sex chromosome disorders.

研究设计

研究类型: Observational
观察模型: Case Control
时间视角: Cross Sectional

入排标准

年龄范围: 11 Weeks 至 22 Weeks（Child）
性别: All
接受健康志愿者: 否

入选标准

•Age ≥18 years
•Fetuses with genetically verified sex chromosome disorders
•Gestational age between 11+0 and 22+6 at the time of abortion or at delivery due to intrauterine fetal death
•Written informed consent
•Inclusion criteria cases:
•Age ≥18 years
•No known sex chromosome disorder or other genetic disorder in the fetus
•No known fetal malformations
•Fetal growth within the normal range
•Gestational age between 11+0 and 22+6 at the time of abortion

排除标准

未提供

结局指标

主要结局

DNA methylation profile

时间窗: 5 years

DNA methylation of placenta DNA methylation across fetal tissues

Gene expression profile

时间窗: 5 years

RNA expression of placenta RNA expression across fetal tissue

次要结局

未报告次要终点

研究者

发起方

University of Aarhus

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

不适用

C-PROWESS study (C-PROWESS study)

jRCTs03121056530

招募中

1 期

Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast CancerA phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

CTIS2023-503606-36-00Institut Gustave Roussy50